In the treatment of aggressive cancers, a single therapeutic modality often faces a fundamental trade-off: local control versus systemic coverage. Surgery and radiotherapy are excellent at eradicating a primary tumor but are powerless against microscopic seeds of disease elsewhere in the body. Conversely, systemic chemotherapy can reach every corner of the circulatory system but often fails to penetrate the dense, resistant core of a large tumor mass.
The research direction emerging across these 76 papers is the strategic, synergistic integration of these modalities. Rather than simply using multiple treatments in sequence, this approach—often termed "multimodal therapy"—seeks to create a "handshake" between local and systemic interventions to overcome resistance mechanisms that neither could defeat alone.
The Local-Systemic Handshake
The most significant shift in this field is the move from additive therapy (1+1=2) to synergistic therapy, where one modality physically alters the tumor to make it more susceptible to another.
A prime example is the combination of local interventional radiology with systemic immunotherapy. In the CHANCE001 study, Hai‐Dong Zhu and colleagues demonstrated that combining Transarterial Chemoembolization (TACE) with PD-(L)1 inhibitors and targeted therapies creates a powerful feedback loop. The TACE procedure causes localized tumor necrosis, which releases a flood of tumor-specific antigens. These antigens act as a "primer" for the immune system, which the systemic checkpoint inhibitors then "activate" to hunt down cancer cells throughout the body.
This synergy can even trigger the abscopal effect, a rare phenomenon where localized treatment causes distant, untreated metastases to shrink. Ping Yin documented this in a case of vaginal melanoma, where a "trimodal" approach of radiotherapy, anti-angiogenic drugs, and immunotherapy induced a systemic response that controlled disease far beyond the radiation field.
Physical Decompression and Biological Control
In many aggressive malignancies, the tumor presents a physical crisis—such as vascular compression or organ obstruction—that drugs cannot solve quickly enough. Researchers like Liang Wang have shown that for resistant vascular tumors, a combination of physical "resets" (like sclero-embolization and microwave ablation) must be paired with localized chemotherapy to resolve life-threatening coagulopathy Experience of a rare case of rebound of the Kasabach-Merritt phenomenon during sirolimus treatment in kaposiform hemangioendothelioma.
Similarly, in the treatment of Small Cell Lung Carcinoma (SCLC), Nobuyuki Hara established that alternating intensive chemotherapy with radiotherapy is essential. The chemotherapy manages the rapid systemic spread characteristic of SCLC, while the radiotherapy prevents the primary site from becoming a "sanctuary" where the cancer can regroup and recur Combination chemotherapy-radiotherapy of small cell carcinoma of the lung.
Downstaging for Curative Intent
Perhaps the most transformative application of multimodal integration is "downstaging"—using aggressive combinations to turn an unresectable, terminal diagnosis into a surgically curable one.
Shiguo Xu reported a case where a patient with advanced liver cancer and lung metastases achieved a complete pathological response through a combination of TACE, targeted therapy (Donafenib), and immunotherapy (Sintilimab). By the time the patient reached the operating table, the primary tumor had been entirely replaced by necrotic tissue, allowing for a curative resection that was previously impossible A Patient With Hepatocellular Carcinoma and Lung Metastasis Successfully Underwent Curative Surgery Following the Downstaging Treatment.
Balancing Intensity and Quality of Life
As these regimens become more complex, the research has also pivoted toward managing the "toxicity cost" of synergy. Jing Gao noted that while combination therapies for vitreoretinal lymphoma double progression-free survival, they significantly increase systemic toxicity Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma.
To counter this, researchers are exploring "less is more" surgical strategies supported by high-intensity adjuvant therapy. Peng Yuan demonstrated that in certain breast cancer cases, omitting invasive lymph node surgery is safe if—and only if—it is compensated for by a robust multimodal regimen of chemotherapy and radiation Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer. This shift treats systemic therapy not just as a backup, but as a primary control mechanism that allows for more conservative, life-preserving local interventions.